X4 Pharmaceuticals (XFOR)

Executive Summary

X4 Pharmaceuticals is a late-stage biopharmaceutical company focused on discovering and commercializing novel therapies for rare diseases of the immune system. Its lead product, XOLREMDI® (mavorixafor), received FDA approval for the treatment of WHIM syndrome, a rare primary immunodeficiency, in 2023. The company is now advancing mavorixafor into Phase 3 development for chronic neutropenic disorders, a broader indication with significant unmet need. The ongoing Phase 3 4WHIM trial (NCT06056297) is recruiting patients and is evaluating mavorixafor's ability to reduce infections and improve neutrophil counts. With a validated mechanism targeting the CXCR4 pathway, X4 is positioned to expand its commercial footprint beyond WHIM syndrome. Financially, the company has a market capitalization of approximately $409 million (estimated) and is publicly traded under the ticker XFOR. X4's near-term value drivers include data readouts from its clinical pipeline and continued commercial execution for XOLREMDI. The company has a Phase 1 hepatic insufficiency study (NCT06858696) expected to complete in April 2026, which could inform dosing in liver-impaired patients. Additionally, the Phase 3 neutropenia trial may yield interim or top-line results in the second half of 2026, representing a major catalyst. If successful, mavorixafor could address a market substantially larger than WHIM syndrome, potentially driving significant shareholder value. The company also benefits from an FDA-approved product already generating revenue, reducing clinical risk compared to pre-commercial biotechs.

Upcoming Catalysts (preview)

• H2 2026Phase 3 4WHIM trial data readout for chronic neutropenia65% success
• Q2 2026Completion and results of Phase 1 hepatic insufficiency study80% success
• 2026Potential label expansion or partnership announcement for mavorixafor50% success